Denali Therapeutics DNLI reported primary analysis data from an early to mid-stage study of its pipeline candidate, tividenofusp alfa (DNL310), in 47 patients with Hunter syndrome (MPS II) over a ...

Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week ...

Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued ...

Research analysts at Zacks Research decreased their FY2024 EPS estimates for shares of Denali Therapeutics in a research report issued on Tuesday, January 28th. Zacks Research analyst A. Chakraborty ...

Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) – Equities research analysts at Leerink Partnrs decreased their FY2025 EPS estimates for shares of Denali Therapeutics in a research note ...

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging” year ...

Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with ...

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging ...

Denali Therapeutics Inc. (DNLI) stock price is 23.30 and Denali Therapeutics Inc. (DNLI) 10-day simple moving average is 23.08. Denali Therapeutics Inc. (DNLI) stock price is 23.30 and Denali ...